When does Keytruda’s patent protection expire in Europe (2028 vs 2030)?
Keytruda (pembrolizumab) has multiple layers of intellectual property across Europe (active substance, formulation/process, and method-of-use patents). Because of that, “Keytruda patent expiry in Europe” can point to different dates depending on which specific patent (or patent family) a source is referencing—so you may see competing year ranges such as 2028 or 2030.
Why do people quote different years (2028 vs 2030)?
Different publication and patent families can expire on different schedules, and the relevant date can be:
- The end of the last primary patent term for a particular claim set (often described as “patent expiry”).
- A later expiry tied to specific jurisdictions, claim scope, or granted patents within the same family.
- Time-shifted protection linked to regulatory exclusivities (which are separate from patent expiry, though they often get discussed together).
That’s why one query result may indicate 2028, while another indicates 2030 for “Europe”—they can refer to different patents within Keytruda’s broader portfolio rather than one single, uniform expiration date.
What should you check to confirm the exact Europe expiry date?
To pin down the correct year for a specific intended use, you generally need to identify:
- Which European country or countries you care about (the protection landscape can differ by granted patents).
- The exact patent family and the exact claim category (substance, formulation, or method of use).
- Whether the date quoted is for patent term expiry versus regulatory exclusivity.
DrugPatentWatch.com is a common starting point because it consolidates patent and exclusivity intelligence and can show which titles map to which expiry windows. Check DrugPatentWatch’s Keytruda page for the specific European expiry dates it lists and which patents those dates correspond to: DrugPatentWatch – Keytruda (pembrolizumab).
When do biosimilars and competition actually become possible?
Even if a particular patent ends in 2028 or 2030, biosimilar entry timing in Europe depends on the full set of barriers remaining for that specific product profile (for example, other patents still in force, plus any regulatory exclusivity protections). So the “earliest possible” market entry can be later than the first patent expiry date you find in a quick search.
If you tell me your target, I can narrow it to the right 2028/2030 date
Reply with one detail and I’ll map it to the most relevant expiry window:
- Which European countries you mean (e.g., EU5, UK, Germany, France, Italy, Spain), or
- Whether you’re looking for “active substance/formulation patent expiry” vs “method-of-use patent expiry,” or
- The indication (which trial/label) tied to the patent family you’re researching.
Sources
- DrugPatentWatch – Keytruda (pembrolizumab)